StockData
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc. (BIAF) income statement

BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3075% below fair value
$1.65−0.20 (-10.81%)

Close on Nov 20, 2026Market cap $13.37MP/E –Yield –

bioAffinity Technologies, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-209.8%
Net margin
-257.3%
Return on equity, FY2025
-301.8%

Financial strength

Current ratio
1.44
Debt to equity
0.01
Debt to assets
0.5%
Cash to current liabilities
90.6%

Valuation

P/E ratio
–
Price to sales
2.27
Price to book
3.55
Dividend yield
–

See a number that looks wrong?